How Plastics Manufacturers Are Valued
Plastics is a category with one of the widest valuation spreads I see. The same nominal business — a 50-person injection molding shop doing $20M in revenue — can transact at anywhere from 4x to 10x EBITDA depending almost entirely on what the shop molds and for whom. Generic industrial parts molders trade at the bottom of the range. FDA-cleared medical device molders, aerospace-grade molders, and clean-room capable shops trade at the top.
Multiples by Size Bracket
Sub-$5M EV businesses in our database trade around 4-5x EBITDA in recent transactions. These are typically owner-operated job shops where the founder is the chief operator and the customer base is regional and concentrated. Buyers discount for transition risk and the small absolute scale.
$5M-$25M EV businesses cluster around 4.5x EBITDA in recent data, though specialty positioning materially shifts this. Generic industrial molders sit at 4-5x; medical molders in this bracket reach 7-9x.
$25M-$100M EV businesses move to roughly 9-10x EBITDA in recent transactions. At this scale buyers are paying for diversified end-markets, multi-plant footprint, and engineering depth (mold design, DFM, secondary operations).
$100M+ EV businesses clear 9-12x EBITDA. Public reference points include Berry Global (BERY) and Atkore (ATKR), which trade at roughly 8-12x EBITDA depending on cycle position. Specialty plastics platforms can clear higher in private auctions.
Specialty Positioning Is Where the Premium Lives
The single biggest decision driving your plastics valuation is what end-markets you serve. FDA-cleared medical device molding — particularly anything ISO 13485 certified, with Class 7 or Class 8 clean rooms, and Class II/III device validation experience — trades at 7-12x EBITDA. Aerospace and defense plastics with AS9100 and ITAR registration trade similarly. These segments have program lifecycles measured in decades and switching costs that effectively lock in customers once qualified.
By contrast, generic packaging molding, automotive Tier 2/3 work, and consumer-product molding without specialty positioning trades at 4-6x EBITDA with limited buyer interest beyond opportunistic strategics. The same physical shop can trade at meaningfully different multiples depending purely on what end-markets the customer base represents.
Customer Concentration Is the Operational Risk
Plastics customer concentration tends to run high — most molders have their top 3 customers at 50-70% of revenue, sometimes more. Buyers price this carefully. Above 40% concentration in a single customer triggers either a 1-2x EBITDA discount or significant escrow tied to that customer's retention post-close.
What helps: long-term supply agreements, sole-source positioning on a specific part number, mold ownership (where the mold lives at your facility under a tolling arrangement), and high switching costs (FDA/ISO qualification, mold tooling investment). Buyers underwrite these protections explicitly when modeling cash flows.
Capex and Mold Tooling Investment
Plastics is capex-heavy in ways that drag headline multiples. Maintenance capex on injection molding presses, auxiliary equipment, and material handling typically runs 3-5% of revenue. Growth capex on new presses, robotics, or clean-room buildouts can be substantial — a single high-tonnage press with full automation can run $1.5M+, and a clean-room expansion can exceed $5M.
Mold tooling adds another wrinkle. In some businesses, molds are customer-owned and live at the shop under tolling agreements. In others, the molder owns the molds and amortizes them across part programs. Buyers diligence the mold ownership question carefully — it affects working capital, customer stickiness, and depreciation profiles.
What Decreases Plastics Value
Resin cost volatility without pass-through clauses is the most common margin compressor. Polypropylene, polyethylene, and engineering resin pricing can move 20-30% in a year. Businesses without contractual pass-through mechanisms face cyclical margin volatility that buyers price into the multiple.
Tariff and supply chain exposure has become more prominent in diligence. Businesses dependent on imported resins, additives, or compounded materials face buyer questions about onshore alternatives and pricing risk.
Sustainability pressure is increasingly relevant. Conventional plastics businesses without recycled-content capability, bio-based resin experience, or alternative material lines face buyer questions about long-term volume durability — particularly in consumer-facing end-markets where brand owners are setting recycled-content commitments.
Environmental regulation adds underwriting risk. Buyers diligence historical Phase I/II environmental conditions, current air permit compliance, and wastewater discharge profiles carefully. Any open environmental issues compress the purchase price or push it into escrow.